Celsion Corp., a biotech company based in Lawrenceville, announced a new name Sept. 19 – one it says reflects the evolution of its business focus and “its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases.”
Now known as Imunon Inc., the company will begin trading on the Nasdaq under the ticker symbol “IMNN,” effective Sept. 21.
The company, whose therapies include one targeting advanced ovarian cancer, has filed an amendment to its articles of incorporation for the name change and has a new logo and website.
“Our new name, Imunon, ideally captures the essence of our scientific endeavors and our mission,” Imunon President and CEO Corinne Le Goff said in a statement. “With this name change, we are underscoring our commitment to create a new category of medicines leveraging our proprietary plasmid DNA technology platform in the fields of immuno-oncology and vaccines.
“With a strong balance sheet supporting current operations into 2025, we are well positioned to build a differentiated company to deliver on the promise of our gene-based therapies,” Le Goff added.